Published Date : 2025-Mar-05
The Global Transcatheter Devices Market is witnessing significant growth, driven by increasing prevalence of cardiovascular diseases, technological advancements, and a growing elderly population. As we move into 2025, key players in the industry continue to innovate, focusing on minimally invasive procedures and advanced catheter-based technologies.
Between 2024 and 2032, the market is projected to grow at a CAGR of 13.2%, from $5.4 Billion in 2023 to $13.35 Billion in 2032.
Edwards Lifesciences, Medtronic, Abbott Laboratories, Boston Scientific Corporation, Artivion, LivaNova, JenaValve, Braile Biomédica, Peijia Medical and Venus MedTech.
Below is a detailed overview of the top companies leading the transcatheter devices market in 2025:
Overview: Edwards Lifesciences Corporation is a global leader in patient-focused medical innovations for structural heart disease, particularly in transcatheter heart valve therapy (THVT). The company pioneered the first commercially available transcatheter aortic valve replacement (TAVR) system, revolutionizing heart valve treatment.
Edwards Lifesciences leads the transcatheter heart valve replacement (TAVR) market with its SAPIEN valve series. The company continues to invest in next-generation heart valves and expand globally.
Edwards Lifesciences continues to dominate the transcatheter devices market, driving innovation in minimally invasive heart valve therapies.
Overview: Medtronic is the world’s largest medical technology company, specializing in cardiac and vascular, minimally invasive therapies, restorative therapies, and diabetes solutions. It has played a pioneering role in transcatheter heart valve replacement (TAVR) and other catheter-based cardiovascular therapies.
The company continues to dominate the transcatheter devices market through advanced technologies, clinical trials, and innovative patient care solutions.
With its cutting-edge transcatheter technologies, Medtronic remains at the forefront of global cardiovascular innovations.
Overview: Abbott Laboratories is a global healthcare and medical devices leader, known for its innovations in cardiovascular, structural heart, diabetes care, and diagnostics. It has a strong presence in transcatheter devices, offering cutting-edge solutions for aortic, mitral, and tricuspid valve diseases.
The company’s Navitor™ TAVR system and MitraClip™ transcatheter mitral valve repair system is among the leading transcatheter therapies in the world.
Abbott continues to lead in transcatheter valve repair and replacement, expanding access to life-saving cardiovascular innovations worldwide.
Overview: Boston Scientific Corporation is a global medical technology leader, specializing in minimally invasive solutions for cardiovascular, structural heart, neurovascular, and endoscopy procedures. The company is renowned for its innovations in transcatheter heart valve replacement (TAVR), atrial fibrillation management, and peripheral vascular therapies.
The company is well known for its Lotus Edge™ and ACURATE neo2™ TAVR systems, focusing on high precision and patient safety.
Boston Scientific continues to lead in transcatheter structural heart solutions, focusing on innovation and global market expansion.
Overview: Artivion, formerly CryoLife, Inc., is a leading innovator in aortic and cardiovascular solutions. The company specializes in transcatheter and surgical heart valve technologies, vascular grafts, and cryopreserved human tissues.
Its focus on aortic repair therapies has positioned Artivion as a key player in the transcatheter heart valve (THV) and endovascular stent-graft market.
Artivion is rapidly emerging as a key player in transcatheter aortic repair and surgical heart solutions, with strong global expansion and cutting-edge innovations.
Overview: LivaNova is a global medical technology company specializing in cardiovascular and neuromodulation solutions. The company was formed through the merger of Sorin Group (Italy) and Cyberonics (USA) in 2015.
LivaNova is a leading innovator in transcatheter heart valve replacement (TAVR), cardiopulmonary bypass systems, and advanced neuromodulation therapies for treating epilepsy and depression.
LivaNova continues to expand in the transcatheter and neuromodulation markets, offering innovative cardiovascular and brain health solutions.
Overview: JenaValve is a specialist medical device company focused on developing next generation transcatheter aortic valve replacement (TAVR) systems. The company is recognized for its unique transapical and transfemoral TAVR solutions, particularly for aortic stenosis and aortic regurgitation patients.
JenaValve is one of the few companies pioneering TAVR therapies specifically for aortic regurgitation (AR), an area where traditional TAVR devices are less effective.
JenaValve is positioned as a key disruptor in the TAVR space, offering specialized solutions for aortic regurgitation where competitors lack dedicated devices.
Overview: Braile Biomédica is a Brazilian medical technology company specializing in cardiovascular, transcatheter, and surgical heart valve solutions. The company is recognized as a pioneer in Latin America for heart valve prostheses, extracorporeal circulation systems, and vascular grafts.
Braile Biomédica was the first company in Latin America to develop a Transcatheter Aortic Valve Replacement (TAVR) system, making minimally invasive heart valve therapy accessible in emerging markets
The company is positioned as Latin America’s leading cardiovascular med-tech company, bringing innovative and affordable transcatheter solutions to emerging markets.
Overview: Peijia Medical is a Chinese medical technology company specializing in transcatheter valve therapies and neurovascular interventions. The company is a leading domestic competitor to global TAVR and neurovascular device manufacturers, focusing on innovative, minimally invasive cardiovascular solutions tailored for the Asian market.
Since its IPO in 2020, Peijia Medical has rapidly expanded its product portfolio and market presence, making significant progress in TAVR (Transcatheter Aortic Valve Replacement) and TMVR (Transcatheter Mitral Valve Replacement) solutions.
Peijia Medical is emerging as a major force in China’s TAVR & neurovascular market, offering cost-effective, innovative transcatheter solutions for cardiovascular and stroke treatment.
Overview: Venus Medtech is China’s leading developer of transcatheter heart valve replacement (TAVR) and mitral valve repair technologies. The company was the first in China to launch a commercial TAVR system, competing with global giants like Medtronic, Edwards Lifesciences, and Abbott.
Since its IPO in 2019, Venus Medtech has expanded internationally, acquiring overseas med-tech firms and advancing next-generation transcatheter therapies.
Venus Medtech is China’s leading TAVR and TMVR innovator, rapidly expanding globally with groundbreaking transcatheter valve solutions.
The global transcatheter devices market is evolving rapidly, with innovation in minimally invasive heart valve therapies leading the way. While North America and Europe continue to dominate, Asia-Pacific is experiencing rapid growth, particularly in China. Companies investing in next-generation devices and expanding global reach will likely lead the market in 2025.
Would you like me to refine this further with additional insights?
Intellectual Market Insights Research is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including, Semiconductor, aerospace, Automation, Agriculture, Food & Beverages, Automotive, Chemicals and Materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports.
